EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?

Marta Novella-Navarro, Ana Van Den Rym iD, Chary López-Pedrera, Ana Martínez-Feito, Beatriz Nieto-Carvalhal iD, Keren Reche, Clementina López-Medina iD, Alejandro Escudero-Contreras iD, Pilar Nozal iD, Maria Eugenia Miranda-Carús, Irene Monjo, Eugenio De Miguel und 3 weitere

Nutrients · 2025

DOI: 10.3390/nu17050820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Marta Novella-Navarro und 14 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Hospital Universitario La Paz, 28046 Madrid, Spain. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Obesity, Janus Kinase Inhibitors, Adipose Tissue. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII) co-financed by European Union and grant awarded by Sociedad de Reumatologia Comunidad de Madrid (SORCOM)., Instiuto de Salud Carlos III (ISCIII).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is a frequent comorbidity in rheumatoid arthritis (RA). This condition may lead these patients to have poorer disease control and a worse response to some of the available treatments.

Objectives

We aim to analyze the role of body mass index (BMI) in the clinical response to Janus kinase inhibitors (JAKis) in patients with RA. We aim to perform an in-depth analysis of the pathophysiology of obesity by assessing serum adipokine levels, their potential influence in disease activity and their changes with treatment.

Methods

This study involved 81 patients with RA treated with JAKis from Hospital La Paz and Hospital Reina Sofía. Patients were classified according to their BMI as normal weight and overweight/obesity. The clinical response to treatment was assessed by the Clinical Disease Activity Index (CDAI) and Disease Activity Score-28 (DAS28) 6 months after the initiation of JAKis. Serum adipokines (leptin and adiponectin) were determined using a commercial immunoassay kit in samples obtained before the initiation of JAKis and after 6 months of treatment.

Results

Leptin levels showed a significant positive correlation with BMI at baseline (r = 0.59, p < 0.01) and at 6 months (r = 0.56, p < 0.01) in the whole cohort, but no correlation was found between BMI and adiponectin. No correlation between disease activity and BMI was found in the whole cohort at baseline and at 6 months measured by both the CDAI and DAS28. Fifty patients (61.7%) achieved low disease activity (LDA)/remission at 6 months, regardless their BMI, and no differences in serum adipokine levels were observed at baseline and at 6 months in patients who achieved LDA vs. no-LDA.

Conclusions

In this study, we did not find an association between obesity and the extent of LDA in patients treated with JAKis; therefore, this mechanism of action could be suitable for overweight/obese patients with RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidObesityJanus Kinase InhibitorsAdipose TissueCytokinesHumansFemaleMaleMiddle AgedBody Mass IndexAgedLeptinAdiponectinAdultTreatment OutcomeAdipokines

Stichwörter der Autor:innen

adipose tissue cytokinesobesityrheumatoid arthritistargeted synthetic disease-modifying antirheumatic drugs

Substanzen

Janus Kinase InhibitorsLeptinAdiponectinCytokinesAdipokines

Autor:innen und Institutionen

  • Rheumatology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • Immuno-Rheumatology Investigation Group, IdiPAZ, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • Laboratory of Immunogenetics of Human Diseases, IdiPAZ, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • Rheumatology Department, Hospital Reina Sofía, IMIBIC, University of Córdoba, 14071 Córdoba, Spain.
  • Immunology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain.

ORCID-Profile: Ana Van Den Rym, Beatriz Nieto-Carvalhal, Clementina López-Medina, Alejandro Escudero-Contreras, Pilar Nozal

Förderung

  • Instituto de Salud Carlos III (ISCIII) co-financed by European Union and grant awarded by Sociedad de Reumatologia Comunidad de Madrid (SORCOM).
  • Instiuto de Salud Carlos III (ISCIII)

Zitieren

APA

Novella-Navarro, M., Van Den Rym, A., López-Pedrera, C., Martínez-Feito, A., Nieto-Carvalhal, B., Reche, K., López-Medina, C., Escudero-Contreras, A., Nozal, P., Miranda-Carús, M. E., Monjo, I., De Miguel, E., Balsa, A., Pérez-De Diego, R., & Plasencia-Rodríguez, C. (2025). Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?. Nutrients. https://doi.org/10.3390/nu17050820

Vancouver

Novella-Navarro M, Van Den Rym A, López-Pedrera C, Martínez-Feito A, Nieto-Carvalhal B, Reche K, et al. Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?. Nutrients. 2025. doi:10.3390/nu17050820

BibTeX
@article{NovellaNavarro2025,
  author = {Novella-Navarro, Marta and Van Den Rym, Ana and López-Pedrera, Chary and Martínez-Feito, Ana and Nieto-Carvalhal, Beatriz and Reche, Keren and López-Medina, Clementina and Escudero-Contreras, Alejandro and Nozal, Pilar and Miranda-Carús, Maria Eugenia and Monjo, Irene and De Miguel, Eugenio and Balsa, Alejandro and Pérez-De Diego, Rebeca and Plasencia-Rodríguez, Chamaida},
  title = {Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17050820}
}
Kostenlos starten →